Opportunity Information: Apply for PAR 24 106
The NIH funding opportunity "Solutions to Enable Regional Genomic Medicine eConsult Services (R43/R44 Clinical Trial Optional)" (Funding Opportunity Number PAR-24-106) is a discretionary grant program aimed specifically at small businesses that can build practical, commercializable solutions to support regional genomic medicine electronic consultation (eConsult) services. In plain terms, NIH is looking for companies to create tools, platforms, workflows, or other implementable products that make it easier for health systems and clinicians to access and deliver genomic medicine expertise through an eConsult model, where a provider can request guidance from a genomics expert without requiring a traditional in-person referral. The emphasis on commercialization signals that NIH wants outcomes that can move beyond a pilot or proof-of-concept and become sustainable products that can be adopted across multiple regions or health systems.
This opportunity uses the SBIR/STTR-style mechanisms R43 and R44, which generally align with phased small business development: an early stage effort to establish feasibility followed by a later stage effort to further develop, validate, and prepare for market. The listing notes "Clinical Trial Optional," meaning applicants are not required to include a clinical trial, but they may propose one if it is appropriate for validating the solution (for example, to test whether the solution improves turnaround time for genomic consults, increases guideline-concordant care, or improves clinician confidence and decision-making). The focus remains on enabling the eConsult service itself rather than funding basic genomic discovery; the target is the infrastructure and operational capability that allows genomic medicine expertise to be delivered efficiently at scale.
Eligibility is limited to small businesses. The notice is explicit that non-U.S. entities (foreign organizations) cannot apply, and non-U.S. components of U.S. organizations are also not eligible to apply. At the same time, it leaves open the possibility of using a "foreign component" as defined by the NIH Grants Policy Statement, which typically refers to discrete project elements performed outside the U.S. under specific circumstances and with NIH approval. Practically, that means the applicant organization must be a qualifying U.S. small business, and any involvement outside the U.S. would need to fit NIH policy and be justified as essential to the project.
From the provided details, the sponsoring agency is the National Institutes of Health, and the program is categorized under Health with CFDA/Assistance Listing number 93.172. The original closing date listed is May 30, 2024, and the opportunity was created on January 9, 2024. The source information does not provide an award ceiling or the expected number of awards, so applicants would need to consult the full NOFO text for budget limits, project period expectations, review criteria, and any NIH institute-specific priorities tied to PAR-24-106. Overall, the core goal is clear: NIH is funding small businesses to produce scalable, market-ready solutions that help regional health care networks deliver genomic medicine expertise through efficient eConsult services.Apply for PAR 24 106
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Solutions to Enable Regional Genomic Medicine eConsult Services (R43/R44 Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.172.
- This funding opportunity was created on 2024-01-09.
- Applicants must submit their applications by 2024-05-30. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Small businesses.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
FAQs: NIH PAR-24-106 (R43/R44) - Solutions to Enable Regional Genomic Medicine eConsult Services
What is the name and number of this NIH funding opportunity?
The funding opportunity is titled "Solutions to Enable Regional Genomic Medicine eConsult Services (R43/R44 Clinical Trial Optional)" and the Funding Opportunity Number is PAR-24-106.
Which agency is offering this grant?
The sponsoring agency is the National Institutes of Health (NIH).
What type of program is this?
This is a discretionary grant program that uses SBIR/STTR-style mechanisms, specifically R43 and R44, which are commonly used for phased small business research and development efforts.
Who is eligible to apply?
Eligibility is limited to small businesses that qualify under the program requirements. The opportunity is aimed specifically at small businesses that can build practical, commercializable solutions.
Are non-U.S. (foreign) organizations eligible to apply?
No. The notice states that non-U.S. entities (foreign organizations) cannot apply.
Can a U.S. small business apply if it has non-U.S. components?
Non-U.S. components of U.S. organizations are not eligible to apply. However, the opportunity notes the possible use of a "foreign component" as defined by the NIH Grants Policy Statement, which would generally mean a discrete project element performed outside the U.S. under specific circumstances and with NIH approval.
What is NIH trying to fund through this opportunity?
NIH is looking for small businesses to create practical, implementable, and commercializable solutions that support regional genomic medicine electronic consultation (eConsult) services. These solutions can include tools, platforms, workflows, or other products that make it easier for health systems and clinicians to access and deliver genomic medicine expertise through an eConsult model.
What is a genomic medicine eConsult in this context?
An eConsult model allows a provider to request guidance from a genomics expert without requiring a traditional in-person referral. The goal is to deliver genomic medicine expertise more efficiently through electronic consultation workflows.
What kinds of solutions are in scope?
Solutions in scope include tools, platforms, workflows, and other implementable products that enable or improve the delivery of genomic medicine expertise via regional eConsult services, with an emphasis on solutions that can be adopted across multiple regions or health systems.
Is this funding intended for basic genomic discovery research?
No. The focus is on enabling the eConsult service itself and supporting the infrastructure and operational capability that allows genomic medicine expertise to be delivered efficiently at scale, rather than funding basic genomic discovery.
What does "commercializable" mean for this opportunity?
The opportunity emphasizes commercialization, signaling that NIH wants outcomes that move beyond a pilot or proof-of-concept and can become sustainable products that can be adopted across multiple regions or health systems.
Which grant mechanisms are used, and what do they generally represent?
The opportunity uses R43 and R44 mechanisms, which generally align with phased small business development: an early stage effort to establish feasibility (often associated with an initial phase) followed by a later stage effort to further develop, validate, and prepare for market.
Are clinical trials required?
No. The opportunity is labeled "Clinical Trial Optional," meaning applicants are not required to include a clinical trial.
Are clinical trials allowed under this opportunity?
Yes. Applicants may propose a clinical trial if it is appropriate for validating the solution, such as testing whether the solution improves turnaround time for genomic consults, increases guideline-concordant care, or improves clinician confidence and decision-making.
What is the CFDA/Assistance Listing number and category?
The opportunity is categorized under Health with CFDA/Assistance Listing number 93.172.
What is the closing date listed for this opportunity?
The original closing date listed is May 30, 2024.
When was this opportunity created?
The opportunity was created on January 9, 2024.
Does the provided information include an award ceiling or the expected number of awards?
No. The provided information does not include an award ceiling or the expected number of awards.
Where should applicants look for budget limits, project period expectations, review criteria, and institute-specific priorities?
Applicants would need to consult the full NOFO text for budget limits, project period expectations, review criteria, and any NIH institute-specific priorities tied to PAR-24-106.
What is the overall goal of this funding opportunity?
The core goal is to fund small businesses to produce scalable, market-ready solutions that help regional health care networks deliver genomic medicine expertise through efficient eConsult services.
Browse more opportunities from the same category: Health
Next opportunity: FY24 IIJA/IRA Bureau of Land Management MT/DAK Threatened and Endangered Species Program
Previous opportunity: Short-Term Research Education Program to Enhance Diversity in Health-Related Research (R25 Clinical Trial Not Allowed)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 24 106
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 24 106) also looked into and applied for these:
| Funding Opportunity |
|---|
| Research on the Impact of and Methods for Implementing Regional Genomic Medicine eConsult Services (U01 Clinical Trials Optional) Apply for RFA HG 24 001 Funding Number: RFA HG 24 001 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Solutions to Enable Regional Genomic Medicine eConsult Services (R41/R42 Clinical Trial Optional) Apply for PAR 24 107 Funding Number: PAR 24 107 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NHGRI Technology Development Coordinating Center (U24 Clinical Trial Not Allowed) Apply for RFA HG 24 013 Funding Number: RFA HG 24 013 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional) Apply for PAR 24 096 Funding Number: PAR 24 096 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders(U01 Clinical Trial Optional) Apply for PAR 24 095 Funding Number: PAR 24 095 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional) Apply for PAR 24 097 Funding Number: PAR 24 097 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional) Apply for PAR 24 098 Funding Number: PAR 24 098 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition: Specific Pathogen Free Macaque Colonies to Support HIV/AIDS Research (U42 Clinical Trial Not Allowed) Apply for PAR 24 129 Funding Number: PAR 24 129 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Understanding Mechanisms and Outcomes of Trained Immunity (R01 Clinical Trial Not Allowed) Apply for PAR 24 112 Funding Number: PAR 24 112 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Understanding Mechanisms and Outcomes of Trained Immunity (R21 Clinical Trial Not Allowed) Apply for PAR 24 111 Funding Number: PAR 24 111 Agency: National Institutes of Health Category: Health Funding Amount: $275,000 |
| Evaluation and Coordinating Center for the AHRQ/PCORI Learning Health System Embedded Scientist Training and Research Centers (U18) Apply for RFA HS 24 002 Funding Number: RFA HS 24 002 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $1,000,000 |
| Novel Approaches for Radiation Biodosimetry Assays and Devices Development (U01 Clinical Trial Not Allowed) Apply for RFA AI 24 003 Funding Number: RFA AI 24 003 Agency: National Institutes of Health Category: Health Funding Amount: $350,000 |
| USAID/Kenya and East Africa Global Health Security (GHS) Activity Apply for 72061524RFI00002 Funding Number: 72061524RFI00002 Agency: Kenya USAID-Nairobi Category: Health Funding Amount: Case Dependent |
| NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required) Apply for PAR 24 099 Funding Number: PAR 24 099 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required) Apply for PAR 24 100 Funding Number: PAR 24 100 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Localization in Health Apply for 620 24 0002 Funding Number: 620 24 0002 Agency: Nigeria USAID-Abuja Category: Health Funding Amount: Case Dependent |
| NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required) Apply for PAR 24 124 Funding Number: PAR 24 124 Agency: National Institutes of Health Category: Health Funding Amount: $350,000 |
| NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required) Apply for PAR 24 116 Funding Number: PAR 24 116 Agency: National Institutes of Health Category: Health Funding Amount: $1,050,000 |
| NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required) Apply for PAR 24 115 Funding Number: PAR 24 115 Agency: National Institutes of Health Category: Health Funding Amount: $350,000 |
| Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Natural Products (Collaborative UG3/UH3 Clinical Trial Required) Apply for PAR 24 123 Funding Number: PAR 24 123 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 24 106", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.